消积饮对晚期非小细胞肺癌患者血清VEGF和肿瘤生长转移的影响  

Clinical Study of Xiaoji Yin on Metastasis and Serum Vascular Endothelial Growth Factor of Patients with Advanced Non-small Cell Lung Cancer

作　　者：李柳宁 李倩[2] 何春霞 柴小姝 逯敏 张力文 刘柏 陈志坚 洪宏喜 

机构地区：[1]广州中医药大学第二附属医院,广州510120 [2]天津中医药大学第一附属医院,天津300193

出　　处：《中国实验方剂学杂志》2014年第12期212-216,共5页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：广东省科技厅计划项目(2007B031402010)

摘　　要：目的:观察消积饮对晚期非小细胞肺癌患者血清血管内皮生长因子(VEGF)的影响和抗晚期非小细胞肺癌患者肿瘤生长与转移的临床综合疗效。方法:对符合受试条件的非小细胞肺癌患者进行前瞻性单盲意向性分组,分为消积饮组、化疗组(化疗+安慰剂)、综合组(消积饮+化疗),每组各45例。消积饮组采用消积饮治疗,化疗组采用NP或GP方案化疗及安慰剂,综合组采用消积饮联合化疗治疗,每21 d为1个治疗周期,共治疗2个周期。治疗前后观察血清VEGF水平的变化、肿瘤大小变化及临床证候、临床症状、行为状况评分的变化,并进行不良反应观察进行药物安全性评价。结果:①消积饮组、综合组治疗后血清VEGF优于治疗前(P<0.05);化疗组治疗前后血清VEGF值相比,差异无统计学意义。②消积饮组的有效率(CR+PR)低于化疗组及综合组;综合组的疾病控制率(CR+PR+SD)高于化疗组、消积饮组(P<0.05);消积饮组的疾病控制率低于化疗组,差异无统计学意义。③在临床证候、临床症状及KPS评分方面,治疗后消积饮组优于化疗组相比(P<0.05);综合组优于化疗组(P<0.05);消积饮组与综合组相比,差异无统计学意义。④在毒副反应方面,消积饮组与化疗组及综合组相比,除1例出现恶心呕吐外,消积饮组没有观察到其他不良反应;化疗组及综合组主要的不良反应为消化道反应、血液系统毒性及肝肾功能影响等。结论:单用消积饮、消积饮联合化疗均可以在一定程度上降低晚期非小细胞肺癌患者血清VEGF表达水平,进一步揭示消积饮抗肿瘤侵袭转移的作用机制之一,可能是通过抑制肿瘤血管生成因子的分泌,减少肿瘤血管生成而实现的。消积饮对晚期非小细胞肺癌的生长有一定抑制作用,与化疗联合应用能提高疾病控制率。单用消积饮、消积饮联合化疗治疗晚期非小细胞肺癌较单纯化疗能更好的改善患者临床�Objective： To observe the influence of Xiaoji yin on the vascular endothelial growth factor （VEGF） of advanced non-small cell lung cancer, and the synthetic clinical curative effects on advanced non-small cell lung cancer. Method： The patients were divided into three groups： Xiaoji yin group, chemotherapy group chemotherapy combined with Xiaoji yin group. Xiaoji yin was administered per day for3 weeks NP or GP was adapted in the chemotherapy combined with Xiaoji yin, the dose and duration were as above. In all the three groups,twoperiods in sequence was an assessment unit. The changes of serum VEGF, the tumor size, improvement of clinical symptoms, common living conditions before and after the treatment were observed. We also monitored the changes of blood routine, liver and renal function, ECG to evaluate the safety of the Xiaoji yin. Result： ①The VEGF： there were differences before and after treatment in group Xiaoji yin and group and chemotherapy combined with Xiaoji yin group. ②The disease remission rate （ CR ＋ PR） of group Xiaoji yin was lower than chemotherapy and chemotherapy combined with Xiaoji yin groups. The disease control rate （ CR ＋ PR ＋ SD） of chemotherapy combined with Xiaoji yin group was higher than chemotherapy and Xiaoji yin groups （P 〈 0. 05 ）. ③The improvement rate of clinical symptoms and the Kamofsky scores stability rate （ascend and stable ）： Xiaoji yin group was higher than chemotherapy group, chemotherapy combined with Xiaoji yin group was higher than chemotherap group （P 〈 0. 05）. ④There is 1 case of nausea and vomiting in group Xiaoji yin. Conclusion： Xiaoji yin or chemotherapy combined with Xiaoji yin can reduce the serum VEGF expression of advanced non-small cell lung cancer. Xiaoji yin could enhanced the disease control rate combined with chemotherapy. Xiaoji yin and chemotherapy combined with Xiaoji yin have effect on improving the clinical symptom and quality of life. Xiaoji yin is safe.

关 键 词：消积饮 非小细胞肺癌 血管内皮生长因子 

分 类 号：R287.6[医药卫生—中药学]